Skip to main content
Journal ArticleOPEN ACCESS

Clinical Outcomes and Costs of Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Inpatients: A Cross-Sectional Study

  • Lenci Marques G
  • De Franca A
  • Saito A
  • et al.
Cureus (2021)
DOI: 10.7759/cureus.15497
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Introduction: Venous thromboembolism (VTE) is the primary cause of preventable death in hospitalized patients in the United States. This is a cross-sectional study with a brief cost analysis of thromboprophylaxis with rivaroxaban and enoxaparin in acutely ill medical inpatients.

Cite

CITATION STYLE

APA

Lenci Marques, G., De Franca, A. C., Saito, A. C., Hornung, F. L., Motter, A. C., Falzoni Pontello, A. C., … Zequinão, T. (2021). Clinical Outcomes and Costs of Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Inpatients: A Cross-Sectional Study. Cureus. https://doi.org/10.7759/cureus.15497

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free